Enzo Biochem Gross Profit 2006-2021 | ENZ

Enzo Biochem gross profit from 2006 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Enzo Biochem Annual Gross Profit
(Millions of US $)
2021 $54
2020 $24
2019 $23
2018 $41
2017 $46
2016 $46
2015 $43
2014 $42
2013 $39
2012 $47
2011 $48
2010 $45
2009 $37
2008 $36
2007 $29
2006 $24
2005 $28
Enzo Biochem Quarterly Gross Profit
(Millions of US $)
2021-07-31 $10
2021-04-30 $16
2021-01-31 $16
2020-10-31 $12
2020-07-31 $8
2020-04-30 $4
2020-01-31 $6
2019-10-31 $6
2019-07-31 $6
2019-04-30 $5
2019-01-31 $5
2018-10-31 $7
2018-07-31 $8
2018-04-30 $11
2018-01-31 $11
2017-10-31 $11
2017-07-31 $10
2017-04-30 $12
2017-01-31 $12
2016-10-31 $12
2016-07-31 $12
2016-04-30 $11
2016-01-31 $11
2015-10-31 $11
2015-07-31 $11
2015-04-30 $10
2015-01-31 $10
2014-10-31 $11
2014-07-31 $11
2014-04-30 $10
2014-01-31 $10
2013-10-31 $11
2013-07-31 $9
2013-04-30 $9
2013-01-31 $9
2012-10-31 $12
2012-07-31 $12
2012-04-30 $12
2012-01-31 $12
2011-10-31 $12
2011-07-31 $12
2011-04-30 $12
2011-01-31 $10
2010-10-31 $13
2010-07-31 $10
2010-04-30 $11
2010-01-31 $11
2009-10-31 $13
2009-07-31 $11
2009-04-30 $10
2009-01-31 $8
2008-10-31 $8
2008-07-31 $8
2008-04-30 $9
2008-01-31 $9
2007-10-31 $10
2007-07-31 $8
2007-04-30 $8
2007-01-31 $6
2006-10-31 $6
2006-07-31 $5
2006-04-30 $6
2006-01-31 $6
2005-10-31 $6
2005-07-31 $7
2005-04-30 $7
2005-01-31 $8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.162B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00